Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2

[1]  H. Linden,et al.  Phase I study of continuous and intermittent schedules of lapatinib in combination with vinorelbine in solid tumors. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  R. Rahmani,et al.  Preclinical and Clinical Pharmacology of Vinca Alkaloids , 2012, Drugs.

[3]  U. Fuhr,et al.  Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors , 2011, Clinical pharmacokinetics.

[4]  T. Dobbins,et al.  The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  J. Bonneterre,et al.  Pharmacokinetic evaluation of the vinorelbine–lapatinib combination in the treatment of breast cancer patients , 2011, Cancer Chemotherapy and Pharmacology.

[6]  T. Dobbins,et al.  The efficacy of HER 2-targeted agents in metastatic breast cancer : a meta-analysis , 2011 .

[7]  A. Cheng,et al.  Abstract P3-14-18: Result of Phase I Part of a Phase I/II Study of Lapatinib (L) Plus Oral Vinorelbine (oVNR) in Metastatic Breast Cancer (MBC) Patients Overexpressing ErbB2 , 2010 .

[8]  E. Chan,et al.  Mechanism-Based Inactivation of Cytochrome P450 3A4 by Lapatinib , 2010, Molecular Pharmacology.

[9]  E. Chan,et al.  Mechanism-Based Inactivation of Cytochrome P 450 3 A 4 by Lapatinib , 2010 .

[10]  F. Esteva,et al.  Her2-positive breast cancer: herceptin and beyond. , 2008, European journal of cancer.

[11]  S. Franco,et al.  A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  A. Chan,et al.  A review of the use of trastuzumab (Herceptin) plus vinorelbine in metastatic breast cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  R. Nahta,et al.  Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling , 2007, Molecular Cancer Therapeutics.

[14]  M. Berger,et al.  Lapatinib plus capecitabine for HER2-positive advanced breast cancer. , 2006, The New England journal of medicine.

[15]  R. Nahta,et al.  HER2 therapy: Molecular mechanisms of trastuzumab resistance , 2006, Breast Cancer Research.

[16]  P. Goss,et al.  Lapatinib: current status and future directions in breast cancer. , 2006, The oncologist.

[17]  T. Delozier,et al.  A phase II study of an oxaliplatin/vinorelbine/5-fluorouracil combination in patients with anthracycline-pretreated and taxane-pretreated metastatic breast cancer , 2006, Anti-cancer drugs.

[18]  H. Sommer,et al.  Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial , 2006, British Journal of Cancer.

[19]  T. Tabei,et al.  [A phase-I clinical study of a combination therapy of vinorelbine and capecitabine in patients with advanced/recurrent breast cancer]. , 2006, Gan to kagaku ryoho. Cancer & chemotherapy.

[20]  V. Gebbia,et al.  Treatment of Metastatic Breast Cancer With Vinorelbine and Docetaxel , 2006, American journal of clinical oncology.

[21]  C. Stewart,et al.  Determination of lapatinib (GW572016) in human plasma by liquid chromatography electrospray tandem mass spectrometry (LC-ESI-MS/MS). , 2006, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[22]  N. Spector,et al.  Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016 , 2004, Oncogene.

[23]  P. Fumoleau,et al.  Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  K. Lackey,et al.  The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. , 2001, Cancer research.

[25]  C. Puozzo,et al.  New sensitive liquid chromatography method coupled with tandem mass spectrometric detection for the clinical analysis of vinorelbine and its metabolites in blood, plasma, urine and faeces. , 2001, Journal of chromatography. A.

[26]  J. Manola,et al.  Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  H. Kobayashi,et al.  CYP3A4 is mainly responsibile for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[28]  T. Kuwabara,et al.  CYP 3 A 4 IS MAINLY RESPONSIBILE FOR THE METABOLISM OF A NEW VINCA ALKALOID , VINORELBINE , IN HUMAN LIVER MICROSOMES , 2000 .

[29]  of efficacy: , 2022 .